Possibilities of a pharmacogenetic approach to solving gynecological problems in patients taking tamoxifen: a literature review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Endocrine therapy for 5–10 years is the standard treatment for women with ER-positive breast cancer (BC). However, the side effects of endocrine therapy with tamoxifen (TAM) reduce the quality of life of BC patients and adversely affect treatment compliance. Currently, the problem of hyperplastic processes and endometrial cancer against the background of long-term use of TAM is especially relevant, because the incidence of endometrial pathology is associated with the duration of TAM use. pharmacogenetics is an important factor predisposing to the occurrence of adverse drug reactions (ADR), incl. endometrial hyperplasia, when taking TAM. Differences in the genes encoding the enzymes CYP2D6, CYP2C9 and CYP2C19, namely, CYP2D6*4, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, as well as the polymorphic marker of the ABCB1 gene (C3435T), encoding the glycoprotein transport protein – P, may be the main predisposition factor to the occurrence of side effects when taking TAM, which in turn leads to a decrease in patient adherence to therapy. However, at the moment, algorithms for monitoring such patients have not been developed, and risk factors that increase the likelihood of ADRs when taking TAM have not been fully identified. An integrated approach to assessing ADRs to TAM, taking into account pharmacogenetic testing data, and resulting predictive models that include both genetic and non-genetic determinants of response may further improve the prediction of individual response to TAM.

Full Text

Restricted Access

About the authors

E. O. Golubenko

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: kate.golubenko@yandex.ru
ORCID iD: 0000-0002-6968-862X

Obstetrician-Gynecologist, Postgraduate Degree Seeker, Department of Obstetrics and Gynecology

Russian Federation, Moscow

M. I. Savelyeva

Yaroslavl State Medical University

Email: kate.golubenko@yandex.ru
ORCID iD: 0000-0002-2373-2250
Russian Federation, Yaroslavl

I. V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Email: kate.golubenko@yandex.ru
ORCID iD: 0000-0002-0995-1801
Russian Federation, Moscow

V. V. Korennaya

Russian Medical Academy of Continuous Professional Education

Email: kate.golubenko@yandex.ru
ORCID iD: 0000-0003-1104-4415
Russian Federation, Moscow

References

  1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020.CA Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21590.
  2. Huang B., Warner M., Gustafsson J.A. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418(Pt. 3):240–44. doi: 10.1016/j.mce.2014.11.015.
  3. Rugo H.S., Rumble R.B., Macrae E., et al. Endocrine therapy for hor- mone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34(25):3069–103. doi: 10.1200/JCO.2016.67.1487.
  4. Марочко Т.Ю., Артымук Н.В., Фетисова Т.И., Сутурина Л.В. Рак молочной железы: что должен знать акушер-гинеколог? Фундаментальная и клиническая медицина. 2018;3(3):84–90. [Marochko T.Y., Artymuk N.V., Fetisova T.I., Suturina L.V. Breast cancer: what should obstetrician-gynecologist know? Fundament Clin Med. 2018;3(3):84–90. (In Russ.)].
  5. Seo J., Lee D., Jo H.G. Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE – Compliant case report. Complement Ther Clin Pract. 2021;43:101378. doi: 10.1016/j.ctcp.2021.101378.
  6. Lee M., Piao J., Jeon M.J. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei Med J. 2020;61(4):317–22. doi: 10.3349/ymj.2020.61.4.317.
  7. Condorelli R., Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert. Rev. Anticancer Ther. 2018;18(11):1101–12. doi: 10.1080/14737140.2018.1520096.
  8. ГЧернуха Г.Е., М.Р. Думановская.. Современные представления о гиперплазии эндометрия. Акушерство и гинекология. 2013;3(3):26–32. [Chernukha G.E., Dumanovskaya M.R. Modern ideas about endometrial hyperplasia. Obstet Gynecol. 2013;3(3):26–32. (In Russ.)].
  9. Мамиконян И.О., Саркисов С.Э., Саттаров Ш.Н. и др. Тамоксифен-ассоцированная патология эндометрия и возможности ее коррекции. Акушерство и гинекология. 2013;(3)33. [Mamikonyan I.O., Sarkisov S.E., Sattarov Sh.N., et al. Tamoxifen-associated endometrial pathology and the possibilities of its correction. Obstet Gynecol. 2013;(3)33–7. (In Russ.)].
  10. Pickar J.H. The endometrium – from estrogens alone to TSECs. Climacteric. 2009;12(6):463–77. doi: 10.3109/13697130903042790.
  11. Чекалова М.А., Махова Е.Е., Шабанов М.А. и др. Значение ультразвукового мониторинга состояния эндометрия у больных раком молочной железы. Опухоли женской репродуктивной системы. 2007;(1–2):17–22. [Chekalova M.A., Makhova E.E., Shabanov M.A., et al. The importance of ultrasound monitoring of the condition of the endometrium in patients with breast cancer. Tumors Female Reprod. Syst. 2007;(1–2):17–22. (In Russ.)].
  12. Харитонова Т.В. Рак тела матки. Современная онкология. 2000;2(2):44–8. [Kharitonova T.V. Cancer of the uterus. Mod Oncol. 2000;2(2):44–8. (In Russ.)].
  13. Goldstein R.B., Bree R.L., Benson C.B., et al. Evaluation of the woman with postmenopausal bleeding: Society of Radio- logists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med. 2001;20(10):1025–36. doi: 10.7863/jum.2001.20.10.1025.
  14. Клинические рекомендации «Рак тела матки и саркомы матки» Министерства здравоохранения Российской Федерации, 2021 год. [Clinical guidelines “Cancer of the uterine body and uterine sarcoma” of the Ministry of Health of the Russian Federation, 2021. (In Russ.)].
  15. Neven P., Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf. 2000;22(1):1–11. doi: 10.2165/00002018-200022010-00001.
  16. Sinawat S., Chiyabutra T. Increased risk of endometrial abnormalities in breast cancer patients taking tamoxifen: the need for gynaecologic surveillance. Asian Pac J Cancer Prev. 2004;5(2):183–87.
  17. Choi S., Lee Y.J., Jeong J.H., et al. Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated with Tamoxifen: A Nationwide Study. Front Oncol. 2021;11:636378. doi: 10.3389/fonc.2021.636378.
  18. Ивашина С.В., Бабаева Н.А. Моцкобили Т.А. и др. Атрофия или гиперплазия эндометрия? Тактика ведения пациенток на фоне антиэстрогенной терапии. Онкология. Журнал им. П.А. Герцена. 2022;11(2):13–9. [Ivashina S.V., Babaeva N.A. Motskobili T.A., et al. Endometrial atrophy or hyperplasia? Tactics of patient management during antiestrogenic therapy. Oncology. J n.a. P.A. Herzen. 2022;11(2):13–9. (In Russ.)]. doi: 10.17116/onkolog20221102113.
  19. Chlebowski R.T., Kim J., Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev. Res. (Phila). 2014;7(4):378–87. doi: 10.1158/1940-6207.CAPR-13-0389.
  20. Chirgwin J.H., Giobbie-Hurder A., Coates A.S., et al. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016;34(21):2452–59. doi: 10.1200/JCO.2015.63.8619.
  21. de Vries Schultink A.H., Zwart W., Linn S.C., et al. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin. Pharmacokinet. 2015;54(8):797–810. doi: 10.1007/s40262-015-0273-3.
  22. Sanchez-Spitman A.B., Swen J.J., Dezentje V.O., et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen, Expert Rev Clin Pharmacol. 2019;12(6):523–36. doi: 10.1080/17512433.2019.1610390.
  23. Singh M.S., Francis P.A., Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast. 2011;20(2):111–18. doi: 10.1016/j.breast.2010.11.003.
  24. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 2005;55(5):471–78. doi: 10.1007/s00280-004-0926-7.
  25. Binkhorst L., Mathijssen R.H., Jager A., van Gelder T. Individuali- zation of tamoxifen therapy: much more than just CYP2D6 geno- typing. Cancer Treat Rev. 2015;41:289–99. doi: 10.1016/j.ctrv.2015.01.002.
  26. Jindal A., Mohi M.K., Kaur M., et al. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. J. Midlife Health. 2015;6(2):59–65. doi: 10.4103/0976-7800.158947.
  27. Brauch H., Murdter T.E., Eichelbaum M., et al. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009;55(10):1770–82.
  28. Relling M.V., Klein T.E. CPIC: clinical pharmacogenetics imple- mentation consortium of the pharmacogenomics research net- work. Clin Pharmacol Ther. 2011;89:464–67. doi: 10.1038/clpt.2010.279.
  29. Chan C.W.H., Law B.M.H., So W.K.W., et al. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 2020;146:1395–404. doi: 10.1007/s00432-020-03206-w.
  30. Saladores P., Murdter T., Eccles D., et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenom J. 2015;15 (1):84–94. doi: 10.1038/tpj.2014.34.
  31. Knox S.K., Ingle J.N., Suman V.J., et al. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamox- ifen (Tam). J Clin Oncol. 2006;24(18):4S–4S.
  32. Schroth W., Goetz M.P., Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429–36. doi: 10.1001/jama.2009.1420.
  33. Sanchez-Spitman A., Dezentje V., Swen J., et al. Tamoxifen pharma- cogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol. 2019;37(8):636–46. doi: 10.1200/JCO.18.00307.
  34. Puszkiel A., Arellano C., Vachoux C., et al. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clin Pharmacol Ther. 2019;106(3):585–95. doi: 10.1002/cpt.1404.
  35. Gunaldi M., Erkisi M., Afsar C.U., et al. Evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisms in Turkish breast cancer patients receiving tamoxifen treatment. Pharmacol. 2014;94(3–4):183–89. doi: 10.1159/000363304.
  36. Dieudonne A.S., Lambrechts D., Smeets D., et al. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Ann Oncol. 2014;25(1):90–5. doi: 10.1093/annonc/mdt399.
  37. Okishiro M., Taguchi T., Jin Kim S., et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952–61. doi: 10.1002/cncr.24111.
  38. Murdter T.E., Schroth W., Bacchus-Gerybadze L., et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708–17. doi: 10.1038/clpt.2011.27.
  39. Province M.A., Goetz M.P., Brauch H., et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 2014;95(2):216–27. doi: 10.1038/clpt.2013.186.
  40. Yang G., Nowsheen S., Aziz K., Georgakilas A.G. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther. 2013;139(3):392–404. doi: 10.1016/j.pharmthera.2013.05.005.
  41. Савельева М.И., Поддубная И.В. Новые возможности фармакогенетического подхода к персонализированной терапии тамоксифеном (обновленный систематический обзор). Фармакогенетика и фармакогеномика. 2020;1:42–56. [Savelyeva M.I., Poddubnaya I.V. New possibilities of a pharmacogenetic approach to personalized therapy with tamoxifen (updated systematic review). Pharmacogenet. Pharmacogenom. 2020;1:42–56. (In Russ.)]. doi: 10.37489/2588-0527-2020-1-42-56.
  42. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187–93. doi: 10.1200/JCO.2007.12.2705.
  43. Gjerde J., Geisler J., Lundgren S., et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC. Cancer. 2010;10:313. doi: 10.1186/1471-2407-10-313.
  44. Bai L., He J., He G.H., et al. Association of CYP2C19 polymorphisms with survival of breast cancer patients using tamoxifen: results of a meta- analysis. Asian Pac J Cancer Prev. 2014;15(19):8331–35. doi: 10.7314/apjcp.2014.15.19.8331.
  45. Human cytochrome P450 (CYP) allele nomenclature T. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http://www.cypalleles.ki.se/cyp2d6.htm. Accessed 23.04.2017.
  46. Del Re M., Citi V., Crucitta S., et al. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? Pharmacol Res. 2016;107:398–406. doi: 10.1016/j.phrs.2016.03.025.
  47. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312–18. doi: 10.1200/JCO.2005.03.3266.
  48. Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9(1):R7. doi: 10.1186/bcr1640.
  49. Wang T., Zhou Y., Cao G. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. Eur J Clin Pharmacol. 2021;77:1095–111. doi: 10.1007/s00228-021-03088-y.
  50. Kiyotani K., Mushiroda T., Imamura C.K., et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 2010.28(8):1287–93. doi: 10.1200/JCO.2009.25.7246.
  51. Sensorn I., Sirachainan E., Chamnanphon M., et al. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenom. Personal Med. 2013;6:93–8. doi: 10.2147/PGPM.S44006.
  52. Argalacsova S., Slanar O., Bakhouche H., Pertuzelka L. Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients. J BUON. 2017;22(5):1217–26.
  53. Swen J.J., Nijenhuis M., de Boer A., et al. Pharmacogenetics: from bench to byte- an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73. doi: 10.1038/clpt.2011.34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Scheme of phase I metabolism of TAM [21]

Download (153KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies